home / stock / argx / argx articles

ARGX Articles, argenx SE

Stock Information
Company Name: argenx SE
Stock Symbol: ARGX
Market: NASDAQ
Website: argenx.com
Menu
ARGX ARGX Quote ARGX Short ARGX News ARGX Articles ARGX Message Board
Get ARGX Alerts

News, Short Squeeze, Breakout and More Instantly...
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024 | Benzinga

July 18, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the live...
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China | Benzinga

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efg...

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting | Benzinga

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN...

FDA Expands Argenx's Vyvgart Label to Treat Rare Disorder | Benzinga

Shares of Argenx (NASDAQ: ARGX) rose nearly 4% on Friday after management announced that the FDA approved its subcutaneously administered Vyvgart H...
Why Is European Drugmaker Argenx Stock Trading Higher On Monday? | Benzinga

Friday, the FDA approved Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy...

Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session | Benzinga

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) share...
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy | Benzinga

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (...

argenx to unveil its 'Vision 2030: Taking Breakthrough Science to 50,000 Patients' during its Upcoming R&D Day on July 16, 2024 | Benzinga

R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprub...

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference | Benzinga

June 4, 2024Amsterdam, the Netherlands – argenx ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives...
Next 10